CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 119 filers reported holding CLOVIS ONCOLOGY INC in Q2 2022. The put-call ratio across all filers is 0.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $107,060 | -37.4% | 53,000 | -15.8% | 0.00% | – |
| Q4 2021 | $171,000 | -37.8% | 62,982 | +2.0% | 0.00% | – |
| Q3 2021 | $275,000 | -17.4% | 61,720 | +7.6% | 0.00% | – |
| Q2 2021 | $333,000 | -1.5% | 57,385 | +19.2% | 0.00% | – |
| Q1 2021 | $338,000 | +36.3% | 48,123 | -7.0% | 0.00% | – |
| Q4 2020 | $248,000 | -10.1% | 51,735 | +9.3% | 0.00% | – |
| Q3 2020 | $276,000 | -9.5% | 47,315 | +9.0% | 0.00% | – |
| Q2 2020 | $305,000 | +44.5% | 43,398 | +30.9% | 0.00% | – |
| Q1 2020 | $211,000 | -34.7% | 33,156 | +6.9% | 0.00% | – |
| Q4 2019 | $323,000 | +156.3% | 31,020 | -1.7% | 0.00% | – |
| Q3 2019 | $126,000 | -72.5% | 31,568 | +2.3% | 0.00% | -100.0% |
| Q2 2019 | $459,000 | -40.7% | 30,854 | -1.0% | 0.00% | 0.0% |
| Q1 2019 | $774,000 | +48.3% | 31,161 | +7.3% | 0.00% | 0.0% |
| Q4 2018 | $522,000 | -42.7% | 29,034 | -6.4% | 0.00% | 0.0% |
| Q3 2018 | $911,000 | -43.1% | 31,034 | -11.8% | 0.00% | -50.0% |
| Q2 2018 | $1,601,000 | -7.0% | 35,202 | +7.9% | 0.00% | 0.0% |
| Q1 2018 | $1,722,000 | -24.4% | 32,618 | -2.6% | 0.00% | 0.0% |
| Q4 2017 | $2,277,000 | -16.9% | 33,486 | +0.7% | 0.00% | -33.3% |
| Q3 2017 | $2,739,000 | -3.8% | 33,260 | +9.4% | 0.00% | 0.0% |
| Q2 2017 | $2,847,000 | +73.9% | 30,408 | +18.3% | 0.00% | +50.0% |
| Q1 2017 | $1,637,000 | +67.9% | 25,709 | +17.1% | 0.00% | +100.0% |
| Q4 2016 | $975,000 | +19.6% | 21,957 | -2.8% | 0.00% | 0.0% |
| Q3 2016 | $815,000 | +162.1% | 22,590 | -0.5% | 0.00% | – |
| Q2 2016 | $311,000 | -14.6% | 22,698 | +20.2% | 0.00% | – |
| Q1 2016 | $364,000 | -43.3% | 18,885 | +2.9% | 0.00% | -100.0% |
| Q4 2015 | $642,000 | -61.6% | 18,360 | +0.9% | 0.00% | -50.0% |
| Q3 2015 | $1,673,000 | +19.1% | 18,189 | +13.8% | 0.00% | 0.0% |
| Q2 2015 | $1,405,000 | +15.1% | 15,986 | -2.9% | 0.00% | 0.0% |
| Q1 2015 | $1,221,000 | +36.9% | 16,458 | +3.4% | 0.00% | +100.0% |
| Q4 2014 | $892,000 | +20.9% | 15,923 | -2.2% | 0.00% | 0.0% |
| Q3 2014 | $738,000 | +11.3% | 16,288 | +1.6% | 0.00% | 0.0% |
| Q2 2014 | $663,000 | -30.9% | 16,032 | +15.9% | 0.00% | -50.0% |
| Q1 2014 | $959,000 | +26.2% | 13,837 | +9.7% | 0.00% | +100.0% |
| Q4 2013 | $760,000 | +10.8% | 12,617 | +11.9% | 0.00% | 0.0% |
| Q3 2013 | $686,000 | -10.6% | 11,276 | -1.5% | 0.00% | 0.0% |
| Q2 2013 | $767,000 | – | 11,442 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |